The associations of nuchal translucency and fetal abnormalities; significance and implications

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 5, 2013, Pages 936-941

  Salman Guraya, Shaista ^a  

^a TAIBAH UNIVERSITY   (Saudi Arabia)

Author keywords

Down's syndrome; First trimester screening; Nuchal translucency; Pregnancy; Prenatal diagnosis

Indexed keywords

BIOLOGICAL MARKER;

AKINESIA; BONE DYSPLASIA; CEREBELLUM HYPOPLASIA; CLEFT FACE; CLINICAL PROTOCOL; CYSTIC LYMPHANGIOMA; DIAPHRAGM HERNIA; DISEASE ASSOCIATION; DOWN SYNDROME; ECHOGRAPHY; FETUS; FETUS DISEASE; FETUS HYDROPS; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; GROWTH RETARDATION; HEART DISEASE; HEPATOMEGALY; HUMAN; NASAL BONE; NUCHAL CORD; NUCHAL TRANSLUCENCY MEASUREMENT; PSYCHOTRAUMA; REVIEW; SCREENING TEST; SECOND TRIMESTER PREGNANCY; SEROLOGY; SKIN EDEMA; SPINE MALFORMATION; UMBILICAL HERNIA;

EID: 84877110719     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/5888.2989     Document Type: Review

References (57)

1. Yoon PW, Olney RS, Khoury MJ, Sappenfield WM, Chavez GF, Taylor D. Contribution of birth defects and genetic diseases to pediatric hospitalizations: a population-based study. Archives of pediatrics & adolescent medicine. 1997;151(11):1096.
2. Souka AP, von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH. Increased nuchal translucency with normal karyotype. American journal of obstetrics and gynecology. 2005;192(4):1005-21.
3. Malone FD, D'Alton ME. First-Trimester Sonographic Screening for Down Syndrome. Obstetrics & amp; Gynecology. 2003;102 (5,Part 1):1066-79.
4. Nevo O, Glanc P. The Role of First-Trimester Anatomy in Obstetrical Ultrasound. Ultrasound Clinics. 2012;7(1):57-73.
5. Lee P, Won H, Chung J, Shin H, Kim A. The variables affecting nuchal skin fold thickness in mid trimester. Prenatal diagnosis. 2003;23(1):60-4.
6. Scheier M, Egle D, Himmel I, Ramoni A, Viertl S, Huter O, et al. Impact of nuchal cord on measurement of fetal nuchal translucency thickness. Ultrasound in obstetrics & gynecology. 2007;30(2):197-200.
7. Taipale P, Ämmälä M, Salonen R, Hiilesmaa V. Learning curve in ultrasonographic screening for selected fetal structural anomalies in early pregnancy. Obstetrics & Gynecology. 2003;101(2):273-8.
8. Bronshtein M, Zimmer EZ. Prenatal ultrasound examinations: for whom, by whom, what, when and how many? Ultrasound in obstetrics & gynecology. 2002;10(1):1-4.
9. Michailidis G, Economides D. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound in obstetrics & gynecology. 2002;17(2):102-5.
10. Sairam S, Carvalho JS. Early fetal echocardiography and anomaly scan in fetuses with increased nuchal translucency. Early Human Development. 2012;88(5):269-72.
11. Hyett J, Moscoso G, Papapanagiotou G, Perdu M, Nicolaides K. Abnormalities of the heart and great arteries in chromosomally normal fetuses with increased nuchal translucency thickness at 1l-13 weeks of gestation. Ultrasound in obstetrics & gynecology. 1996;7(4):245-50.
12. Clur S, Ottenkamp J, Bilardo C. The nuchal translucency and the fetal heart: a literature review. Prenatal diagnosis. 2009;29(8):739-48.
13. Cheng EY. Prenatal Diagnosis: Noninvasive Screening. Ultrasound Clinics. 2011;6(1):1-10.
14. Bekker M. A normal 20 week scan of a euploid fetus with a history of first trimester increased nuchal translucency: caution or reassurance? Ultrasound in obstetrics & gynecology. 2007;30(1):8-10.
15. Westin M, Saltvedt S, Bergman G, Almström H, Grunewald C, Valentin L. Is measurement of nuchal translucency thickness a useful screening tool for heart defects? A study of 16 383 fetuses. Ultrasound in obstetrics & gynecology. 2006;27(6):632-9.
16. Bahado-Singh RO, Wapner R, Thom E, Zachary J, Platt L, Mahoney MJ, et al. Elevated first-trimester nuchal translucency increases the risk of congenital heart defects. American journal of obstetrics and gynecology. 2005;192(5):1357-61.
17. Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH. Challenges in the diagnosis of fetal non chromosomal abnormalities at 11-13 weeks. Prenatal diagnosis. 2011;31(1):90-102.
18. Rasiah S, Publicover M, Ewer A, Khan K, Kilby M, Zamora J. A systematic review of the accuracy of first trimester ultrasound examination for detecting major congenital heart disease. Ultrasound in obstetrics & gynecology. 2006;28(1):110-6.
19. SCOTT F, BOOGERT A, SINOSICH M, ANDERSON J. Establishment and application of a normal range for nuchal translucency across the first trimester. Prenatal diagnosis. 1998;16(7):629-34.
20. Mogra R, Alabbad N, Hyett J. Increased nuchal translucency and congenital heart disease. Early Human Development. 2012;88(5):261-7.
21. Berdahl LD, Wenstrom KD, Hanson JW. Web neck anomaly and its association with congenital heart disease. American journal of medical genetics. 2005;56(3):304-7.
22. Cicero S, Sacchini C, Rembouskos G, Nicolaides KH. Sonographic Markers of Fetal Aneuploidy-A Review. Placenta. 2003;24, Supplement. 2(0):S88-S98.
23. Smith D. First-Trimester Nuchal Translucency Screening to Detect Down Syndrome. Newborn and Infant Nursing Reviews. 2008;8(1):e1-e6.
24. Wald N, Rodeck C, Hackshaw A, Rudnicka A. SURUSS in perspective. Semin Perinatol. 2005;29(4):225-35.
25. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, et al. First-trimester screening for trisomies 21 and 18. Obstetrical & gynecological survey. 2004;59(3):177.
26. Stewart TL, Malone FD, editors. First trimester screening for aneuploidy: nuchal translucency sonography. Seminars in perinatology. 1999: Elsevier.
27. Malone FD, D'Alton ME. First-trimester sonographic screening for Down syndrome. Obstetrics & Gynecology. 2003;102(5):1066-79.
28. De Biasio P, Siccardi M, Volpe G, Famularo L, Santi F, Canini S. First trimester screening for Down syndrome using nuchal translucency measurement with free hCG and PAPP A between 10 and 13 weeks of pregnancy-the combined test. Prenatal diagnosis. 1999;19(4):360-3.
29. Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free-hCG and pregnancy-associated plasma protein-A Human Reproduction. 2008;23(9):1968-75.
30. Canick JA, Kellner LH, editors. First trimester screening for aneuploidy: serum biochemical markers. Seminars in perinatology. 1999: Elsevier.
31. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study. BJOG: An International Journal of Obstetrics & Gynaecology. 2003;109(6):667-76.
32. Bindra R, Heath V, Liao A, Spencer K, Nicolaides K. One stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound in obstetrics & gynecology. 2002;20(3):219-25.
33. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. New England Journal of Medicine. 2005;353(19):2001-11.
34. Wald N, Watt H, Hackshaw A. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. New England Journal of Medicine. 1999;341(7):461-7.
35. Orlandi F, Bilardo C, Campogrande M, Krantz D, Hallahan T, Rossi C, et al. Measurement of nasal bone length at 11-14 weeks of pregnancy and its potential role in Down syndrome risk assessment. Ultrasound in obstetrics & gynecology. 2003;22(1):36-9.
36. Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides K. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. The lancet. 2001;358(9294):1665-7.
37. Hutchon DJR, Monni G, Hjalgrim H, de Biasio P, Venturini P, Reynolds T, et al. Absence of nasal bone and detection of trisomy 21. Lancet. (London, England). 2002;359(9314):1343.
38. Wald N, Rodeck C, Hackshaw A, Walters J, Chitty L, Mackinson A. SURUSS Research Group. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess. 2003;7:1-77.
39. D'Alton M, Cleary-Goldman J, editors. First and second trimester evaluation of risk for fetal aneuploidy: the secondary outcomes of the FASTER Trial. Seminars in perinatology. 2005: Elsevier.
40. Hyett J, Brizot M, Von Kaisenberg C, McKie A, Farzaneh F, Nicolaides K. Cardiac gene expression of atrial natriuretic peptide and brain natriuretic peptide in trisomic fetuses. Obstetrics & Gynecology. 1996;87(4):506-10.
41. Clark EB. Neck web and congenital heart defects: A pathogenic association in 45 X O Turner syndrome? Teratology. 2005;29(3):355-61.
42. Lacro RV, Jones KL, Benirschke K. Coarctation of the aorta in Turner syndrome: a pathologic study of fetuses with nuchal cystic hygromas, hydrops fetalis, and female genitalia. Pediatrics. 1988;81(3):445-51.
43. Simpson J, Sharland G. Nuchal translucency and congenital heart defects: heart failure or not? Ultrasound in obstetrics & gynecology. 2002;16(1):30-6.
44. Driscoll DA, Morgan MA, Schulkin J. Screening for Down syndrome: changing practice of obstetricians. American journal of obstetrics and gynecology. 2009;200(4):459. e1-e9.
45. Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. Bmj. 1999;318(7176):81-5.
46. Goetzl L. Adverse Pregnancy Outcomes After Abnormal First-Trimester Screening for Aneuploidy. Clinics in Laboratory Medicine. 2010;30(3):613-28.
47. Spencer K. Accuracy of Down syndrome risks produced in a first-trimester screening programme incorporating fetal nuchal translucency thickness and maternal serum biochemistry. Prenatal diagnosis. 2002;22(3):244-6.
48. Ghi T, Huggon I, Zosmer N, Nicolaides K. Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype. Ultrasound in obstetrics & gynecology. 2001;18(6):610-4.
49. Mavrides E, Cobian Sanchez F, Tekay A, Moscoso G, Campbell S, Thilaganathan B, et al. Limitations of using first trimester nuchal translucency measurement in routine screening for major congenital heart defects. Ultrasound in obstetrics & gynecology. 2001;17(2):106-10.
50. Petrikovsky BM, Baker D, Schneider E. Fetal hydrops secondary to human parvovirus infection in early pregnancy. Prenatal diagnosis. 1999;16(4):342-4.
51. Bilardo C, Pajkrt E, De Graaf I, Mol B, Bleker O. Outcome of fetuses with enlarged nuchal translucency and normal karyotype. Ultrasound in obstetrics & gynecology. 2002;11(6):401-6.
52. Markov D, Jacquemyn Y, Leroy Y. Bilateral cleft lip and palate associated with increased nuchal translucency and maternal cocaine abuse at 14 weeks of gestation. Clinical and experimental obstetrics & gynecology. 2003;30(2-3):109.
53. Clementschitsch G, Hasenohrl G, Steiner H, Staudach A. Early diagnosis of a fetal skeletal dysplasia associated with increased nuchal translucency with 2D and 3D ultrasound. Ultraschall in der Medizin. 2003;24(5):349-52.
54. Geipel A, Berg C, Germer U, Krapp M, Kohl M, Gembruch U. Mucopolysaccharidosis VII (Sly disease) as a cause of increased nuchal translucency and non immune fetal hydrops: study of a family and technical approach to prenatal diagnosis in early and late pregnancy. Prenatal diagnosis. 2002;22(6):493-5.
55. Sharp P, Haan E, Fletcher J, Khong TY, Carey W. first trimester diagnosis of smith-lemli-opitz syndrome. Prenatal diagnosis. 1998;17(4):355-61.
56. Hiippala A, Eronen M, Taipale P, Salonen R, Hiilesmaa V. Fetal nuchal translucency and normal chromosomes: a long term follow up study. Ultrasound in obstetrics & gynecology. 2002;18(1):18-22.
57. Scholl J, Iyer C, Heard A, Coletta J, Panda B, Russell M. 415: Thicker nuchal translucency is associated with greater risk of abnormal fetal and neonatal outcomes among fetuses with first trimester cystic hygroma. American Journal of Obstetrics and Gynecology. 2011;204(1, Supplement):S168.